Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LoBULarDIPG: Low Dose Bevacizumab with Radiotherapy in DIPG
NCT04250064Phase 2Recruiting
- Sponsor
- Tata Memorial Centre
- Start
- Feb 2020
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in diffuse intrinsic pontine glioma (DIPG), sponsored by Tata Memorial Centre. Started Feb 2020; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
diffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT04250064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04250064.